Citius Oncology, Inc.
NASDAQ:CTOR · NASDAQ Global Market
+$0.03 today
Vol 0.03M · Avg 0.12M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.2%
avg -45.2%
ROIC
-45.7%
avg -39.3%
ROA
-24.5%
avg -25.4%
Analysis
ROA is currently the strongest return metric at -24.5% versus its period average of -25.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Myron Z. Holubiak | Executive Vice Chairman & Secretary | $450,000.00 | — | 79 | $850,000.00 | 0.91% |
Myron S. Czuczman | Executive Vice President & Chief Medical Officer | $225,000.00 | — | 66 | $850,000.00 | 0.91% |
Leonard L. Mazur | Chief Executive Officer, President & Executive Chairman | $166,250.00 | — | 81 | $1.70M | 1.83% |
Jaime Bartushak | Chief Financial Officer & Treasurer | — | — | 58 | $825,000.00 | 0.89% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Forte Biosciences, Inc.
NASDAQ:FBRX
$248.90M
Fate Therapeutics, Inc.
NASDAQ:FATE
$235.93M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$127.96M
Vor Biopharma Inc.
NASDAQ:VOR
$100.68M
Owlet, Inc.
NYSE:OWLT
$92.46M
LENSAR, Inc.
NASDAQ:LNSR
$69.48M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$63.62M
Scilex Holding Company
NASDAQ:SCLX
$57.49M
Actuate Therapeutics Inc
NASDAQ:ACTU
$50.01M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages CTOR?
Citius Oncology, Inc. (CTOR) lists 4 active executives. The top listed executive is Myron S. Czuczman, Executive Vice President & Chief Medical Officer.
Are CTOR insiders buying or selling?
Recent insider activity shows net buying of $27.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.